TickerFacts.

Dyne Therapeutics, Inc. (DYN): Long-Term Debt

Annual figures by period end, from SEC filings.

$148.92M
As of 2025-12-31
$199.33M
As of 2026-06-30
2024-12-31: $02025-12-31: $148.92M$148.92M
2024-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$148.92Mn/a2026-03-02, Balance as of period end
2024-12-31$0n/a2026-03-02, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Dyne Therapeutics, Inc. (DYN)2025-12-31$148.92Mn/a
Arcus Biosciences, Inc. (RCUS)2025-12-31$99.00M+106.3%
Madrigal Pharmaceuticals, Inc. (MDGL)2025-12-31$339.88M+189.1%
Pacira BioSciences, Inc. (PCRX)2025-12-31$372.19M-36.4%
Harmony Biosciences Holdings, Inc. (HRMY)2025-12-31$163.66M-8.7%
Emergent BioSolutions Inc. (EBS)2025-12-31$589.70M-15.8%
Cytokinetics Inc (CYTK)2024-12-31$619.52M-3.1%
Cogent Biosciences, Inc. (COGT)2025-12-31$222.90Mn/a
BridgeBio Pharma, Inc. (BBIO)2025-12-31$2.01Bn/a

Compare DYN, RCUS, MDGL, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗